Elicio Therapeutics, Inc. (ELTX) Financial Statements (2025 and earlier)

Company Profile

Business Address 451 D STREET, 5TH FLOOR
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments26,016,0003,425,00011,853,00012,894,00014,841,00021,682,000
Cash and cash equivalent26,016,0003,425,00011,853,00012,894,00014,841,00021,682,000
Restricted cash and investments1,318,000396,000665,000722,0001,671,000 
Prepaid expense453,000647,000178,000376,000496,000714,000
Other undisclosed current assets2,859,0002,221,0001,434,0002,356,0002,923,0003,829,000
Total current assets:30,646,0006,689,00014,130,00016,348,00019,931,00026,225,000
Noncurrent Assets
Operating lease, right-of-use asset5,926,0006,142,0006,354,0006,563,0006,768,0006,952,000
Property, plant and equipment523,000597,000635,000717,000772,000919,000
Prepaid expense600,0001,632,0002,673,0002,833,0002,833,0002,842,000
Restricted cash and investments693,000690,000688,000685,000683,000681,000
Total noncurrent assets:7,742,0009,061,00010,350,00010,798,00011,056,00011,394,000
TOTAL ASSETS:38,388,00015,750,00024,480,00027,146,00030,987,00037,619,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,836,0006,376,0004,429,0008,126,0008,822,0006,580,000
Accounts payable1,984,0001,055,0001,105,0004,369,0004,406,0004,265,000
Accrued liabilities4,852,0005,321,0003,324,0003,757,0004,416,0002,315,000
Deferred revenue1,307,000350,000627,000694,0001,664,000 
Deferred compensation liability  5,00014,00025,00036,000 
Other undisclosed current liabilities877,000854,000881,000921,000964,0001,017,000
Total current liabilities:9,020,0007,585,0005,951,0009,766,00011,486,0007,597,000
Noncurrent Liabilities
Long-term debt and lease obligation      
Long-term debt, excluding current maturities      
Liabilities, other than long-term debt5,338,0005,565,0005,791,0006,007,0006,215,0006,465,000
Deferred compensation liability, classified      46,000
Operating lease, liability5,338,0005,565,0005,791,0006,007,0006,215,0006,419,000
Other undisclosed noncurrent liabilities43,016,0004,252,0007,868,000   
Total noncurrent liabilities:48,354,0009,817,00013,659,0006,007,0006,215,0006,465,000
Total liabilities:57,374,00017,402,00019,610,00015,773,00017,701,00014,062,000
Equity
Equity, attributable to parent(18,986,000)(1,652,000)4,870,00011,373,00013,286,00023,557,000
Common stock108,000103,000102,00096,00084,00084,000
Treasury stock, value(150,000)(150,000)(150,000)(150,000)(150,000)(150,000)
Additional paid in capital161,355,000159,892,000159,218,000153,827,000146,631,000146,221,000
Accumulated other comprehensive loss(202,000)(238,000)(270,000)(197,000)(25,000)(2,000)
Accumulated deficit(180,097,000)(161,259,000)(154,030,000)(142,203,000)(133,254,000)(122,596,000)
Total equity:(18,986,000)(1,652,000)4,870,00011,373,00013,286,00023,557,000
TOTAL LIABILITIES AND EQUITY:38,388,00015,750,00024,480,00027,146,00030,987,00037,619,000

Income Statement (P&L) (USD)

12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
Gross profit:   (3,000)   
Operating expenses(10,344,000)(10,924,000)(10,238,000)(9,392,000)(10,771,000)(7,777,000)
Operating loss:(10,344,000)(10,924,000)(10,241,000)(9,392,000)(10,771,000)(7,777,000)
Nonoperating income (expense)(8,494,000)3,695,000(1,586,000)443,000113,000218,000
Investment income, nonoperating185,000137,000    
Gain (loss), foreign currency transaction, before tax(1,000)(9,000)153,000249,000(33,000)(9,000)
Interest and debt expense(137,000)(49,000)(36,000)1,000(1,000)604,000
Loss from continuing operations before income taxes:(18,975,000)(7,278,000)(11,863,000)(8,948,000)(10,659,000)(6,955,000)
Other undisclosed loss from continuing operations      
Net loss:(18,975,000)(7,278,000)(11,863,000)(8,948,000)(10,659,000)(6,955,000)
Other undisclosed net income (loss) attributable to parent137,00049,00036,000(1,000)1,000(604,000)
Net loss available to common stockholders, diluted:(18,838,000)(7,229,000)(11,827,000)(8,949,000)(10,658,000)(7,559,000)

Comprehensive Income (USD)

12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
Net loss:(18,975,000)(7,278,000)(11,863,000)(8,948,000)(10,659,000)(6,955,000)
Comprehensive loss:(18,975,000)(7,278,000)(11,863,000)(8,948,000)(10,659,000)(6,955,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent173,00081,000(37,000)(173,000)(22,000)(606,000)
Comprehensive loss, net of tax, attributable to parent:(18,802,000)(7,197,000)(11,900,000)(9,121,000)(10,681,000)(7,561,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: